Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690490 | 0.78 | NCF1 (0.64) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL1257332 | 0.78 | BACE1 (0.44) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL323374 | 0.78 | NCF1 (0.64) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL29726892 | 0.78 | BACE1 (0.44) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL1848398 | 0.75 | NCF1 (0.60) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL362901 | 0.75 | CYP1A2 (0.64) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL1120035 | 0.75 | NCF1 (1.00) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL8511566 | 0.75 | MAOA (0.50) | ACHEALDH1A1HPGDKDM4EGLA | |
| SCHEMBL1845376 | 0.75 | NCF1 (0.60) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL29850612 | 0.75 | NCF1 (0.60) | NCF1ACHEALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112521387-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-112521387-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-112074516-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2020-12-11 | — | — | CN | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| CN-105377851-B | BET bromodomain inhibitors and therapeutic methods using these inhibitors | 密执安州立大学董事会 | 2018-07-20 | — | — | CN | disclosed |
| EP-2970312-B1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| CN-103476766-B | Heterocyclic compound and they are as the purposes of glycogen synthase kinase-3 inhibitors | ABBVIE德国有限责任两合公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-105377851-A | BET bromodomain inhibitors and therapeutic methods using these inhibitors | UNIV MICHIGAN REGENTS | 2016-03-02 | — | — | CN | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
| CN-103476766-A | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO KG | 2013-12-25 | — | — | CN | disclosed |
| EP-2323661-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIV LEIDEN (NL) | 2013-04-17 | — | — | EP | disclosed |
| CN-102123709-A | A3Adenosine receptor allosteric modulators | UNIV LEIDEN | 2011-07-13 | — | — | CN | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | NCF1 3051/4885ACHE 433/4885ALDH1A1 2719/4885 |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | NCF1 339/4885ACHE 3006/4885ALDH1A1 677/4885 |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | NCF1 1023/4885ACHE 4615/4885ALDH1A1 4162/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | NCF1 1023/4885ACHE 4615/4885ALDH1A1 4162/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | NCF1 1023/4885ACHE 4615/4885ALDH1A1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.